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Multiple myeloma (MM) is a malignancy of terminally-differentiated plasma cells that develops mainly inside the
bone marrow (BM) microenvironment. It is well known that autocrine and paracrine signals are responsible for
the progression of this disease but the precise mechanism and contributions from single cell remain largely un-
known. Mesenchymal stem cells (MSC) are an important cellular component of the BM: they support MM growth
by increasing its survival and chemo-resistance, but little is known about the paracrine signaling pathways. Three-
dimensional (3D) models of MM-MSC paracrine interactions are much more biologically-relevant than simple 2D
models and are considered essential for detailed studies of MM pathogenesis.
Herein we present a novel 3D co-culture model designed to mimic the paracrine interaction between MSC and
MM cells. MSC were embedded within a previously characterized thermoresponsive block copolymer worm gel
that can induce stasis in human pluripotent stem cells (hPSC) and then co-cultured with MM cells. Transcriptional
phenotyping of co-cultured cells indicated the dysregulation of genes that code for known disease-relevant factors,
and also revealed IL-6 and IL-10 as upstream regulators. Importantly, we have identiﬁed a synergistic paracrine
signaling pathway between IL-6 and IL-10 that plays a critical role in sustaining MM cell proliferation.
Our ﬁndings indicate that this 3D co-culture system is a useful model to investigate the paracrine interaction
between MM cells and the BM microenvironment in vitro. This approach has revealed a new mechanism that
promotes the proliferation of MM cells and suggested a new therapeutic target.1. Introduction
Multiple myeloma (MM) is a B-cell neoplasia that develops within the
bone marrow (BM) microenvironment that sustains the induction, se-
lection and expansion of cancer cells [1–3]. The abnormal growth of
malignant plasma cells is strongly dependent on autocrine and paracrine
loops involving the surrounding microenvironment that supports MM
cell proliferation, survival, migration and chemo-resistance [4,5].
Many new autocrine and/or paracrine myeloma growth factors have
been identiﬁed [6,7]. However, the contribution of individual cell types is
still largely unknown, making it difﬁcult to understand intercellular
communication signaling in MM. Mesenchymal stem cells (MSC) are a key
cellular component of the BM; they are capable of self-renewal and differ-
entiation and are known to play multiple roles in tumor progression [8,9].
MSC support MM cell growth, survival and drug resistance through para-
crine circuits [10,11], but little is known about the respective mechanisms.Pandit).
form 16 December 2019; Accepte
evier Ltd. This is an open accessComparison of MSC derived from the BM of myeloma patients (MM-
MSC) with those from normal donors (ND-MSC) suggests that MM-MSC
provide efﬁcient support for MM cell migration [12]. Within hours of
co-culture with MM cells, normal MSC can become in vitroMM-MSC that
display a phenotype similar to that of patient-derived MM-MSC [13].
This phenotype is characterized by abnormally high production of solu-
ble regulatory factors such as cytokines, chemokines and growth factors
that play a fundamental role in the crosstalk between MM cells and MSC
[14].
To investigate the role of this crosstalk in the pathogenesis and pro-
gression of MM, appropriate in vitro models are considered essential.
However, current MM in vitro studies mainly involve two-dimensional
(2D) cell culture [15], which are unable to reproduce the desired phys-
iological response. Moreover, animal models are inadequate predictors
for human MM disease and drug response owing to their inter-species
differences. These problems highlight the urgent need for mored 18 December 2019
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The importance of using 3D models to elucidate physiological in-
teractions has long been recognized in the ﬁeld of tissue engineering [16,
17], but this important concept has only recently been introduced to
study MM pathogenesis and progression [18,19].
In view of these considerations, we have developed a novel co-culture
system between BM-derived MSC and MM cells to mimic the in vivo
paracrine interaction. For this purpose, we embedded MSC within a
wholly synthetic, highly biocompatible thermoresponsive hydrogel [20].
More speciﬁcally, a poly(glycerol monomethacrylate)
-block-poly-(2-hydroxypropyl methacrylate) (PGMAPHPMA) diblock
copolymer is synthesized via RAFT (reversible addition-fragmentation
chain transfer) aqueous dispersion polymerization in the form of
worm-like micelles, which interact to afford a soft, free-standing gel via
multiple inter-worm contacts [21]. Importantly, this well-characterized
formulation [22,23] is a hydroxyl-rich mucin-mimicking hydrogel
capable of maintaining pluripotent stem cells in their dormant,
non-proliferative G0 state [24]. Such quiescence is reversible and is an
intrinsic in vivo property of pluripotent (and multipotent) stem cells that
can be also induced in vitro [25–27].
RNA-seq transcriptomic proﬁling of MSC and MM cells indicated
broad changes in both cell types as a consequence of co-culture, which
enabled us to verify our hypothesis of a paracrine loop involving IL-6 and
IL-10 that sustains MM cell proliferation.
Overall, this study provides new insights for understanding the effect
of paracrine signals between MSC and myeloma cells, and highlights the
pivotal role played by MSC in the pathophysiology of MM.
2. Material and methods
2.1. Cell culture
MM cell lines RPMI-8226, MM1S and JJN3 (kindly provided by Prof.
Michael O'Dwyer, National University of Ireland, Galway, IE) were
cultured in RPMI 1640 medium (Sigma-Aldrich, St Louis, MO,
http://www.sigmaaldrich.com) supplemented with 10% FBS (Fetal
bovine serum, Gibco, Thermo Scientiﬁc, Waltham, MA, http://www.th
ermofisher.com), 60 mg/ml penicillin, and 100 mg/mL streptomycin
(Sigma-Aldrich) and incubated at 37 C in a humidiﬁed atmosphere
containing 5% CO2.
MSC derived from human bone marrow aspirates (kindly provided by
Prof. Dimitrios Zeugolis, National University of Ireland, Galway, IE) were
isolated using a protocol previously described [28], and cultured in
complete medium (MEM alpha, GlutaMAX supplemented with 10% fetal
bovine serum and 1% penicillin/streptomycin), and maintained at 37 C
in a humidiﬁed atmosphere containing 5% CO2.
2.2. Protocol for the synthesis of PGMA52 Macro-CTA
PGMA52 (G52) was synthesized as follows: CPDB RAFT agent (0.864 g,
3.9 mmol) and GMAmonomer (25.0 g, 156.1 mmol) were weighed into a
100 mL round-bottomed ﬂask and purged under N2 for 30 min. ACVA
initiator (218.6 mg, 0.78 mmol; CTA/ACVA molar ratio ¼ 5.0) and
anhydrous ethanol (49.6 mL; previously purged with N2 for 30 min) were
then added, and the resulting red solution was degassed for a further
10 min. The ﬂask was subsequently sealed and immersed into an oil bath
set at 70 C. After 100 min, the polymerization was quenched by opening
to air, immersing in liquid nitrogen for 30 seconds followed by dilution
with methanol (100mL). A ﬁnal GMA conversion of 78%was determined
by 1H NMR analysis. The methanolic solution was precipitated into a ten-
fold excess of dichloromethane. After ﬁltering and washing with
dichloromethane, the crude polymer was dissolved in water and the re-
sidual dichloromethane was evaporated under vacuum. The resulting
aqueous solution was freeze-dried overnight to yield a pink powder. 1H
NMR analysis indicated a mean degree of polymerization of 52 for this
PGMA macro-CTA. DMF GPC indicated a number average molecular2weight, Mn of 14 800 and a molar mass dispersity, Mw/Mn of 1.10
(Fig. S1, Supporting Information).
2.3. Protocol for the synthesis of PGMA52 - PHPMA122 diblock copolymer
PGMA macro-CTA (0.726 mmol, 6.74 g), hydroxylpropyl methacry-
late (92.0 mmol, 13.26 g Target DP ¼ 130) and ACVA (0.143 mmol,
0.040 g, 5:1 CTA:initiator) were weighed into a 1000mL round bottomed
ﬂask ﬁtted with a two-necked ﬂange lid and an overhead stirrer. 180 mL
deionized water was added to the ﬂask and the stirrer was turned on so as
to maintain the solid components in suspension while dissolving. During
this process, a nitrogen needle attached to a schlenk line was inserted
through a rubber septum placed in one of the reactor ports and nitrogen
was bubbled through the reaction mixture for 45 min in order to remove
traces of oxygen. After this period, the nitrogen needle was raised above
the surface of the liquid and the ﬂask was immersed into an oil bath set to
70 C. After three hours the reaction was terminated by opening to air
and immersing the ﬂask into an ice-bath. Once cooled, the viscous liquid
was transferred into dialysis tubing (3000 MWCO) and dialysed for one
week, with twice daily water changes to ensure all small-molecule im-
purities were removed. The dispersion was then transferred into a
1000 mL round bottomed ﬂask and placed in the freezer overnight before
freeze drying to form a pink powder. 1H NMR analysis indicated a
copolymer composition of PGMA52-PHPMA122 based on a HPMA
monomer conversion of 94% (Fig. S2, Supporting Information). DMF
GPC indicated a number average molecular weight, Mn of 35 500 and a
molar mass dispersity,Mw/Mn of 1.14 (Fig. S1, Supporting Information).
2.4. 1H NMR spectroscopy
1H NMR spectra were recorded in CD3OD using a 400 MHz Bruker
Avance-400 spectrometer (64 scans averaged per spectrum).
2.5. Gel permeation chromatography (GPC)
Copolymer molecular weights and molar mass dispersities were
determined using an Agilent 1260 Inﬁnity DMF GPC operating at 60 C
and equipped with two Polymer Laboratories PL gel 5 μm Mixed-C col-
umns and a guard column. The GPC eluent was HPLC grade DMF con-
taining 10 mM LiBr at a ﬂow rate of 1.0 mL min1. DMSO was used as a
ﬂow-rate marker. The refractive index detector was used for calculation
of molecular weights and molar mass dispersities by calibration using a
series of ten near-monodisperse poly(methyl methacrylate) standards
(Mn ¼ 625 618 000 g mol1).
2.6. Oscillatory rheology studies
An AR-G2 rheometer equipped with a variable temperature Peltier
plate and a 40 mm 2 aluminum cone was used in oscillatory mode to
measure loss modulus (G00) and storage modulus (G0) as a function of
temperature. Temperature sweeps were conducted at an applied strain
amplitude of 1.0% and at an angular frequency of 1 rad s1. Measure-
ments were recorded at 1 C intervals, allowing 3 min for thermal
equilibration between points. The critical gelation temperature (CGT)
was noted as the temperature at the crossover point for G’ and G”
(Fig. S3, Supporting Information).
2.7. Three-dimensional cell culture
A 10% w/v PGMA52-PHPMA122 worm gel dispersed in the MSC cul-
ture medium was cooled to 4 C to induce degelation via a worm-to-
sphere transition, affording a free-ﬂowing dispersion of copolymer
spheres. This cold, low-viscosity ﬂuid was then ultraﬁltered using a
sterile 0.20 μm syringe ﬁlter. Syringes and ﬁlters were stored at 20 C
for at least 1 h prior to ultraﬁltration to prevent gelation on contact. The
resulting sterilized copolymer worm gel was then used to encapsulate
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2.8. Cell viability assay
The alamarBlue® (Invitrogen, Carlsbad, NY, http://www.invit
rogen.com) assay was used to evaluate the metabolic activity of MSC in
the 3D cell culture system. At each time point, 10% alamarBlue® in
Phosphate Buffer Saline (PBS) was added to assess the cell metabolic
activity after 2, 4 and 7 days, the absorbance was measured at the
wavelengths of 550 nm and 595 nm using a microplate reader (Varioskan
Flash, ThermoScientiﬁc). The level of metabolic activity was determined
using the simpliﬁed method of calculating % of reduction, according to
the supplier's protocol. The LIVE/DEAD® assay (Molecular Probes, Life
Technologies, Eugene, OR) was also used to visualize the distribution of
living and dead cells in the gel at the same time points. Cell viability was
evaluated using calcein AM and ethidium homodimer-1 (EthD-1). The
calcein binds to live cells and produces green ﬂuorescence, while EthD-1
binds to dead cells and produces red ﬂuorescence. The staining solution
was prepared in PBS at a concentration of 2 μM calcein and 4 μM EthD-1.
Fluorescence images were recorded using a Fluoview 1000 Confocal
Microscope (Olympus).
2.9. Cell proliferation assays
Cell proliferation was determined using a PicoGreen® ﬂuorescent
DNA quantiﬁcation kit (Molecular Probes, Life Technologies) for both 3D
and 2D cultures at 2, 4 and 7 days as described by the manufacturer.
Recovery of cells from 3D cultures was obtained by centrifuging the gel in
PBS at 4 C. Brieﬂy, 100 μl DNA samples were incubated with 100 μl
diluted (1:200) PicoGreen® reagent in Tris EDTA (TE) buffer in a 96-well
opaque, ﬂat-bottomed assay plate. Fluorescence was read at 485 nm and
525 nm, and then compared with a DNA standard curve. For inhibition
experiments, MM cell cultures were treated with combinations of IL-6, IL-
10 and blocking antibodies (R&D Systems, Minneapolis, MN) in serum-
free media at a concentration of 100 ng/ml for 24 h.
Proliferation of cells after treatment with IL-6 and IL-10 was tested
using PicoGreen® and BrdU assay (Sigma-Aldrich), which detects incor-
poration of 5-bromo-20-deoxyuridine in proliferating cells. Plates were
read at 450 nm wavelength.
2.10. RNA isolation
RNA was isolated from MSC and MM cells both mono-cultured and
co-cultured for 12 h using an Arcturus® PicoPure® RNA isolation kit
(Applied Biosystems, Waltham, MA, http://www.thermofisher.com) ac-
cording to the manufacturer's instructions. RNA quality and quantity
were measured using 2100 Bioanalyser and RNA 6000 Pico Kit, as per
standard protocol (Agilent Technologies, Santa Clara, CA). Samples with
a RIN (RNA integrity number) value > 9 were used for RNA-seq analysis.
2.11. RNA-sequencing
After cell retrieval and total RNA extraction as described above,
samples were submitted to Genewiz (South Plainﬁeld, NJ, http
s://www.genewiz.com), where mRNA enrichment and library prepara-
tion were performed. Individual samples were bar-coded and run on a
HiSeq 2500 sequencer (Illumina, San Diego, CA). The data presented
here represents the sequencing of three pooled replicates from three in-
dependent experiments per sample.
2.12. Ingenuity Pathway Analysis
RNA-seq data were analyzed using Qiagen's Ingenuity® Pathway
Analysis software (IPA®, Qiagen Redwood City, CA, www.qiagen.com/
ingenuity). Two parameters were taken into consideration to determine
the signiﬁcance of the association between the input data set and the3functions or pathways: (1) a ratio of the number of genes from the data
set that map to the function/pathway divided by the total number of
genes that map to the function/pathway and (2) a p-value calculated
using Fischer's exact test determining the probability that the association
between the genes in the dataset and the function/pathway is explained
by chance alone. DAVID Gene Functional Classiﬁcation Tool (http://dav
id.abcc.ncifcrf.gov) was used for the functional enrichment analyses on
IL-6 and IL-10 target genes.
2.13. Cytokine protein array and ELISA
Supernatants from mono/co-cultures were harvested after 24 and
48 h and analyzed with a human inﬂammation cytokine antibody array
(RayBio® Inﬂammation Antibody Array C series; Raybiotech Parkway,
GA) that enables the simultaneous detection of 40 cytokines. All analyses
were performed according to the manufacturer's guidelines. Concentra-
tions of IL-10 and IL-6 in mono/co-culture supernatants and lysates were
measured using ELISA kits (R&D Systems), as per standard protocol.
Colorimetric absorbance was recorded at 450 nm.
2.14. PathScan® sandwich immunoassay
This commercially-available immunoassay (Cell Signaling Technol-
ogy, Danvers, MA) was used according to the manufacturer's instructions.
Brieﬂy, cell lysates were harvested after 24 h of mono and co-culture
using the buffer provided with the kit. The Array Blocking Buffer was
added to each well and incubated for 15 min at room temperature.
Subsequently, the lysate was added to each well and incubated overnight
at 4 C. After washing, the detection antibody cocktail was added to each
well and incubated for 1 h at room temperature. Horseradish peroxidase
(HRP)-linked streptavidin was added to each well and incubated for
30 min at RT. The slide was then covered with Clarity™ ECL (Bio-Rad)
and images were captured using a digital imaging system (Bio-Rad).
Image J version 1.46r (NIH, http://imagej.nih.gov/) was used for spot
quantiﬁcations.
2.15. Statistical analysis
All data are expressed as mean  standard deviation of triplicate
samples. Comparisons between multiple groups were performed using
one-way ANOVA and Tukey's post hoc test. All analyses were performed
with GraphPad Prism 5 (San Diego, CA). Differences between two data-
sets were considered signiﬁcant if P < 0.05.
3. Results
3.1. 3D model characterization
3.1.1. Establishment of MM-MSC co-culture system using diblock copolymer
worm gel
A thermoresponsive PGMA52-PHPMA122 worm gel with a critical
gelation temperature of 19 C, as judged by oscillatory rheology studies
(Fig. S3, Supporting Information) [20], was used to embed MSC in a
co-culture system with RPMI 8226 Multiple Myeloma cell line (MM) to
study the paracrine interaction. This 3D model is illustrated in Fig. 1A.
Brieﬂy, MSC were encapsulated within a 10% w/v thermoresponsive
aqueous copolymer dispersion and, before gelation, added to a transwell
and transferred to a 24-well plate containing MM cells. The following
systems were examined: (i) MSC in 3D culture alone, (ii) MSC in 3D
co-cultured with MM cells and (iii) MM cells alone.
3.1.2. MSC morphology, viability and proliferation within PGMA52 -
PHPMA122 worm gel
After MSC encapsulation within the worm gel, the cell morphology
was evaluated using a confocal microscope. A rounded morphology was
observed and the MSC were uniformly distributed throughout the gel
Fig. 1. Co-culture system and MSC
encapsulation characterization. A)
Schematic representation of the co-
culture system. B) Electron microscopy
image of the worm gel (left) and contrast
phase image of encapsulated MSC
(right). C) Cellular metabolic activity for
encapsulated MSC expressed as 3D vs 2D
percentage difference. D) Representative
confocal Z-stack images of encapsulated
MSC stained with calcein AM (live,
green) and ethidium homodimer (dead,
red) viability staining kit at 2, 4 and 7
days of culture. Scale bar ¼ 50 μm. E)
Cellular proliferation determined by
PicoGreen® assay after recovering the
DNA from cells in both 3D and 2D cul-
ture. (N ¼ 3 independent experiments,
*p < 0.05, * *p < 0.01, * * *p < 0.001).
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marBlue® assay. These experiments indicated a signiﬁcant increase be-
tween day 2 (78.0  2.6%) and day 4 (90.7  2.1%) but remained stable
at day 7 (91.0 3.6%) (Fig. 1C). Unseeded worm gels alone were used as
negative controls and tissue culture plastic (2D) seededMSCwere used as4a positive control. The LIVE/DEAD® assay was employed to visualize the
distribution of living and dead cells after 2, 4 and 7 days in the 3D cell
culture system. A few dead cells were observed after 7 days but the vast
majority of cells remained alive at this time point (Fig. 1D). To assess the
rate of proliferation, the cell-encapsulated worm gels were cooled to 4 C
Fig. 2. RNA-seq analysis of co-cultured MSC and MM cells. A) Venn Diagram of differentially expressed (DE) genes in co-cultured MM cells, B) MSC and C)
common DE genes. Genes with a fold change greater than two (the absolute value of log2 fold change greater than unity) and an adjusted p-value less than 0.05 were
considered to be DE genes. D) The most activated and statistically signiﬁcant canonical pathways in co-cultured MM vs. mono-cultured MM cells and F) co-cultured
MSC vs. mono-cultured MSC identiﬁed using the IPA® software are listed according to their p-value (-log); the threshold -log(p-value) ¼ 1.3 corresponds to a p-value of
0.05. E) Functional enrichment analysis and predicted activation/inhibition statuses in co-cultured MM vs. mono-cultured MM cells and G) co-cultured MSC vs. mono-
cultured MSC identiﬁed using the IPA® software; threshold: activation z-score ¼ 2, inhibition z-score ¼ 2; Fisher's Exact Test. (N ¼ 3 pooled replicates from three
independent experiments).
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Fig. 3. Upstream regulator analysis of the differentially expressed genes in co-cultured MM cells. A) Upstream regulators in the co-cultured MM cells identiﬁed using
the IPA® Upstream Regulator Analysis (URA) tool. B) IL-6 mechanistic network from IPA® showing network regulators and some of the differentially expressed
downstream genes (IRF4, ABCG2, CD38, CD163L1, CX3CR1, CCR1). Shades of red indicate the degree of upregulation, while shades of green represent the degree of
downregulation. The edges connecting the nodes are colored orange when leading to activation of the downstream node, blue when leading to inhibition, yellow if the
ﬁndings underlying the relationship are inconsistent with the state of the downstream node, and grey if the effect is not predicted. Pointed arrowheads indicate that
the downstream node is expected to be activated, while blunt arrowheads indicate that the downstream node is expected to be inhibited. IL-10C) and IL-6 D)
downstream genes. (N ¼ 3 pooled replicates from three independent experiments).
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analysis. DNA content was quantiﬁed using the PicoGreen® assay after 2,
4 and 7 days and compared to MSC grown in a 2D cell culture model
(Fig. 1E). While the DNA concentration from encapsulated cells increased
across all time points (78.0 10.4 ng/ml at day 2, 102.1 10.9 ng/ml at
day 4 and 112.3  9.4 ng/ml at day 7), the rate of proliferation from 3D-
seeded cells was signiﬁcantly lower than that of 2D-seeded cells
(103.7  7.7 ng/ml at day 2, 139.6  12.6 ng/ml at day 4 and
136.0  11.7 ng/ml at day 7). This is consistent with the metabolic ac-
tivity data. We have previously demonstrated that this polymer exhibits
comparable gel moduli to natural mucins, and that this mucin-mimicking
3D gel is able to maintain Pluripotent Stem Cells (PSC) in a G0 quiescent
state, without inducing proliferation or differentiation commitment, but
maintaining the potential to do it. These properties make our system
unique when compared to previous ones, because of the state in which
MSC are maintained, owing to the relationship between the cell-material
interaction and cell fate determination [24].
3.2. Differential gene expression proﬁling and pathway analysis of MSC
and MM cells in co-culture
To investigate the molecular consequences of co-culture, RNA-seq
analysis was performed on bothmono- and co-cultured MM andMSC.We
applied a 5% false discovery rate (FDR), an adjusted p-value  0.05, and
fold change 1.0 log2 for up- or down-regulation as the criteria to deﬁne
differentially-expressed (DE) genes. As per the above criteria, 760 genes
were DE in MM cells following co-culture with MSC. Of these, 667 genes
were up-regulated, whereas 83 genes were down-regulated (Fig. 2A); in
MSC co-cultured with MM, 1099 genes were DE, and, of these, 718 were
up-regulated and 381 were down-regulated (Fig. 2B); common DE genes
were 69 (Fig. 2C). Among the most differentially-expressed genes in co-
cultured MM cells, we identiﬁed a chemokine (C-X-C motif) receptor to
be highly over-expressed, with a fold change (FC) of 182.6, namely
CX3CR1. The CX3CL1/CX3CR1 axis has been previously implicated in
the interaction between multiple myeloma cells and the bone microen-
vironment, and also associated with cell survival and disease progression
[29]. Interestingly, we also found the transcription factor IRF4 (inter-
feron regulatory factor 4) to be up-regulated in the co-culture condition
(FC ¼ 19.54); this transcription factor has been reported to be essential
for the survival of MM cells [30]. Moreover, we found several genes
involved in the positive regulation of B cell activation and proliferation
such as Bcl-2 (B-cell lymphoma 2, FC ¼ 2.38), CD38 (FC ¼ 10.38),
NCKAP1L (Nck-associated protein 1-like, FC ¼ 8.94) and TLR9 (Toll-like
receptor 9, FC ¼ 29) to be over-expressed in co-culture. On the other
hand, MSC in co-culture with MM cells showed up-regulation of several
chemokine ligands (CXCL6, FC ¼ 3.66; CXCL8, FC ¼ 8.17; CXCL9,
FC ¼ 3.09; CXCL10, FC ¼ 2.85; CCL2, FC ¼ 4.56 and CCL7, FC ¼ 15,62)
reported to regulate cell trafﬁcking and migration of immune cells
[31–33], and interleukins (IL-7, FC ¼ 2.43; IL-10, FC ¼ 13.83; IL-22,
FC ¼ 3.37; IL-32, FC ¼ 3.06) with immuno-modulatory properties
[34–37].
We next performed pathway and functional enrichment analyses
using IPA® to identify pathways that were altered by the co-culture
condition. The most activated pathways in MM co-cultured with MSC
were mainly related to immune response and B cell activation (Fig. 2D),
e.g. PI3K signaling in B lymphocytes and B cell receptor signaling. In
contrast, the Triggering Receptor in Myeloid cell 1 (TREM1) signaling, a
proinﬂammatory immune response and a regulator of Toll-Like7Receptors (TLR) signaling, was the most signiﬁcant activated pathway
for MSC (Fig. 2F).
In addition, we conducted a functional enrichment analysis to iden-
tify the most statistically-signiﬁcant functional categories associated with
DE genes in co-culture. We found that the functional categories that were
more enriched in MM cells were relative to “inﬂammatory response”,
“cellular growth” and “cellular movement” (Fig. 2E), whereas for MSC
the functional categories were “cell-to-cell signaling”, “hematological
system development and function”, “cancer” and “cell death and sur-
vival” (Fig. 2G).
3.3. Upstream regulator analysis reveals activated IL-6 and IL-10 signaling
in co-cultured MM cells
To further investigate the mechanism behind the observed changes in
expression, we used the Upstream Regulator Analysis (URA) which is a
tool implemented within the IPA® software to identify the molecules
upstream of the genes in the dataset and their associated networks [38].
We performed URA on co-cultured MM cells to identify potential up-
stream regulators induced by the paracrine interaction with MSC and
able to modulate different functions in MM. Using this approach for the
most signiﬁcant upstream regulators (Bonferroni corrected
p-value < 0.05), we found some of the cytokines reported to be impli-
cated with MM progression (Fig. 3A) including IL-6 and IL-10, which
were reported to be involved in MM cell proliferation [39,40]. Interest-
ingly, the causal effect of the upstream regulator IL-6 on the data set, as
evidenced in the mechanistic network (Fig. 3B), was predicted to be
relayed also through IL-10, which was found to be upregulated in
co-cultured MSC (FC ¼ 13.8). Moreover, this network also inﬂuences the
expression of some of the overexpressed genes in MM discussed in the
previous paragraph, i.e. CX3CR1, IRF4 and CCR1. In particular, MM cells
display 19 DE genes that are targeted by IL-10 (Figure 3C) and 30 tar-
geted by IL-6 (Fig. 3D). The only relationship involving inhibition that is
predicted to be consistent is downregulation of the FOS proto-oncogene
among the IL-10 targeted genes, in agreement with previous ﬁndings
[41]. We performed functional classiﬁcation analyses of these DE genes
using DAVID software package [42]. This analysis indicated that the
biological category “Pathways in cancer” is the most enriched for IL-10
targeted genes (Table 1) and “Cytokine-Cytokine receptor interaction”
for the IL-6 targeted genes (Table 2). Several genes of these categories
were up-regulated in MM cells as a result of co-culture with MSC, indi-
cating a possible activation state. In the following sections, we focus on
the validation and quantiﬁcation of the hypothesized alterations sug-
gested by the pathway and functional classiﬁcation analyses.
3.4. Crosstalk between MSC and MM cells induces IL-6 and IL-10 secretion
To better understand the crosstalk between MM and MSC cells and to
elucidate how the co-culture inﬂuences the cytokine secretion proﬁle, a
cytokine protein array was conducted on media from mono- and co-
culture conditions after 24 and 48 h, respectively (Fig. 4A and S4A,
Supporting information). Thus, we identiﬁed a characteristic “cytokine
signature” associated with the co-culture condition. In particular, we
observed a signiﬁcant increase in IL-6, IL-8 and IL-10 in co-culture media
relative to monocultured MM after 24 and 48 h, while IL-11 only
increased after 48 h (Fig. 4B). With respect to mono-cultured MSC, the
co-cultured media exhibited an increase in IL-10 and IL-6 after 24 and
48 h, and CCL1, CXCL9, IL-11, IFN-γ and IL-1α only after 48 h (Fig. 4C).
Table 1
Functional annotation analysis using DAVID software of the IL10-downstream
genes. Enrichment scores 1 are considered signiﬁcant.
Biological category
(KEGG_PATHWAY)
Enrichment
score
Genes
Pathway in cancer 2.65 BCL2, E2F, FOS, SPI1,
PDGFB, TGFA
HTLV-I infection 2 E2F, FOS, MYB, SPI1,
PDGFB
Cytokine-cytokine receptor
interaction
1.62 CCR1, CCR3, CX3CR1,
PDGFB
Table 2
Functional annotation analysis using DAVID software of the IL6-downstream
genes. Enrichment scores 1 are considered signiﬁcant.
Biological category
(KEGG_PATHWAY)
Enrichment
score
Genes
Cytokine-cytokine receptor
interaction
2.48 CCR1, CX3CR1, TNFRSF13B,
CSF2RB, IL12RB2
T cell receptor signaling
pathway
2.36 CCR1, FOS, PIK3CG, TLR9
B cell receptor signaling
pathway
1.68 FCGR2B, FOS, INPP5D, PIK3CG
R. Spelat et al. Materials Today Bio 5 (2020) 100040The consistent upregulation of IL-6 and IL-10 suggested potential
roles for these interleukins in the crosstalk between MM and MSC cells.
To verify this hypothesis, we ﬁrst validated the greater secretion of IL-6
and IL-10 using ELISA. As expected, a signiﬁcant increase in the pro-
duction of IL-6 (MM cells: 67.5 1.3 pg/ml; MSC 3D: 2656 188 pg/ml;
co-culture: 3046 84 pg/ml at 48 h) and IL-10 (MM cells: 19.3 1.5 pg/
ml; MSC 3D: 9.7  0.7 pg/ml; co-culture: 234  35 pg/ml at 48 h) was
observed in co-culture (Fig. 4D and E). To understand whether MSC and/
or MM cells were responsible for this induced IL-6 and IL-10 secretion,
we conducted further ELISA studies on cell lysates. These additional
experiments conﬁrmed that the MSC were mainly responsible for the
enhanced secretion of IL-6 and IL-10 (Figs. S5A and S5B, Supporting
Information). Moreover, we have evaluated the secretion of IL-6 and IL-
10 after co-culture with MSC in an additional MM cell line, MM1S. The
results obtained evidenced an induction of the secretion of both cyto-
kines after co-culture, supporting our previous ﬁndings (Figs. S5C and
S5D, Supporting Information).
3.5. IL-6 and IL-10 synergistically sustain the proliferation of MM cells
Cytokines act through signal-transduction pathway activation [43].
In particular, IL-6 and IL-10 signal mainly via activation of the tran-
scription factor Stat3 [44,45]. To assess the activation states for different
pathways, cell lysates deriving from mono and co-cultures were analyzed
using the PathScan® Intracellular Signaling Array Kit for the simulta-
neous detection of 18 important and well-characterized phosphorylated
signaling molecules (Fig. 5A and S4B, Supporting Information). These
data conﬁrmed increased phosphorylation of Stat3 in both MSC and MM
cells after co-culture (Fig. 5B). Moreover, IL-10 signaling induction
through Stat3 activation was also supported by IPA® analysis (Fig. 5C).
In cancer cells, aberrant IL-6 signaling and constitutive activation of
Stat3 are closely related to cell proliferation and drug resistance [46]. To
investigate whether IL-6 and IL-10 secreted by MSC support MM cells
proliferation by paracrine stimulation, we ﬁrst compared MM cells pro-
liferation in mono and co-culture to examine whether there was any
evidence for enhanced proliferation under the latter conditions. We
observed an increase in the rate of proliferation in MM cells (Fig. S6A,
Supporting Information), but not in MSC (Fig. S6B, Supporting Infor-
mation) as a consequence of co-culture. Moreover, IL-6 and
IL-10-neutralizing antibody treatments reduced the proliferation of
co-cultured MM cells (Fig. S6C, Supporting Information). Consistently,
exogenous IL-6 (100 ng/ml) and IL-10 (100 ng/ml) signiﬁcantly8increased the proliferation of mono-cultured MM cells, as demonstrated
by PicoGreen® and BrdU assays (Figs. S6D–E, Supporting Information).
Given that IL-6 has been reported as a proliferative factor for MM cells
[47], is overexpressed by MSC after co-culture, and also signals through
IL-10, we explored the possibility that IL-6 and IL-10 have a synergistic
effect on the proliferation of MM cells. Cell proliferation assays
conﬁrmed a signiﬁcant additional increase after concomitant treatment
with IL-6 and IL-10, suggesting that IL-10 works in tandem with IL-6 to
sustain MM cell proliferation, while neutralizing antibodies markedly
reduced the rate of proliferation of MM cells (Fig. 5D).
To further validate these results, we analyzed the proliferation rate
after treatment with IL-6 and IL-10 in an additional MM cell line, JJN3
cells, obtaining similar results to RPMI-8226 cells, and suggesting that IL-
6 and IL-10 can be considered as key players in MM (Figs. S6F–G, Sup-
porting Information).
4. Discussion
Investigation of the paracrine mechanisms involved in MM patho-
genesis, progression and resistance to treatments requires the develop-
ment of suitable in vitromodels to determine the individual contributions
of speciﬁc cell types to the overall response [19]. In this study, we
focused our attention on the contribution of MSC, an essential element of
the BM niche that profoundly inﬂuences the behavior of MM cells [10,
48]. Speciﬁcally, we have developed a co-culture system that mimics the
paracrine interaction between MSC and MM cells, while using a 3D
(rather than 2D) culture system to more accurately represent multiple
myeloma growth. Previously, we reported the characterization of a
wholly synthetic thermoresponsive diblock copolymer hydrogel that of-
fers a decisive advantage over commercial protein-based gels [20]
because it can maintain hPSC in their quiescent state [24], which is
similar to the situation encountered in vivo. Accordingly, encapsulation of
MSC within this thermoresponsive copolymer hydrogel enabled us to
evaluate a co-culture system that provides a 3D environment for MSC
while maintaining MM cells in suspension culture (their natural 3D
environment). This new approach leads to a much more physically
realistic in vitro model.
Chemokine receptors and their ligands play a crucial role in the
migration of plasma cells to and from the BM, as well as inﬂuencing their
chemotaxis within the BM microenvironment [31–33]. Multiple
myeloma cells express various chemokine receptors and secrete several
chemokines, which contribute to cell homing, tumor growth, and pro-
gression [9,49]. The expression of CX3CR1 (also known as fractalkine)
has recently been detected in human myeloma cell lines and is reported
to induce osteoclast differentiation. In particular, the CX3CL1/CX3CR1
axis supports cooperation between multiple myeloma and osteoclast cells
to promote adhesion of MM cells to bone extra cellular matrix (ECM),
which is a required process for disease progression [29]. In our study, we
have conﬁrmed the expression of this chemokine and interestingly
veriﬁed its over-expression as a consequence of co-culture with MSC.
This suggests that the crosstalk between MSC and MM cells modulates
the interaction with osteoclast cells and their differentiation, which in
turn forms the basis of the MM-induced bone lesion owing to an imbal-
ance between osteoblasts and osteoclasts [50,51].
Another remarkable effect on MM cells after co-culture is up-
regulation of the interferon transcription factor 4 (IRF4). IRF4 is a
member of the interferon regulatory family and has emerged as a master
regulator in multiple myeloma, controlling a regulatory network to
which MM cells are addicted, and that is essential for their survival. IRF4
directs B cell to plasma cell differentiation, immunoglobulin class
switching and is overexpressed in cells derived from MM patients [30].
IRF4 up-regulation in MM cells after exposure to MSC is associated
with greater secretion of IFN-γ in co-culture and suggests a pro-survival
feedback. Moreover, the “inﬂammatory response” and “cellular prolif-
eration” functional categories were identiﬁed as the most statistically
signiﬁcant ones associated with upregulated genes in co-cultured vs.
Fig. 4. Co-culture enhances IL-6 and IL-10 secretion. A) Representative images of cytokine array scans performed on the culture media of MM, MSC and co-
cultured cells after 24 and 48 h of culture. IL-6 and IL-10 are framed within blue and red rectangles, respectively. B) Dot plots of cytokine array quantiﬁcations of
co-cultured vs mono-cultured MM cells and C) co-cultured vs mono-cultured MSC at 24 and 48 h. D) IL-6 and E) IL-10 ELISA quantiﬁcation of the respective su-
pernatants derived from MM cells, MSC in monolayer culture (MSC 2D), encapsulated MSC (MSC 3D) and MM cells plus MSC 3D (co-culture) after 24 and 48 h of
culture. (N ¼ 3 independent experiments, *p < 0.05, * *p < 0.01, * * *p < 0.001).
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Fig. 5. Activation of IL-6 and IL-10 signaling sustains proliferation of MM cells. A) Representative scans of PathScan® Intracellular Signaling Arrays showing Stat3
pathway activation in MSC and MM cells. B) Heatmaps of arrays quantiﬁcation. C) IL-10 signaling induction in MSC indicated using IPA® software. Shades of red
indicate the degree of upregulation, while shades of green represent the degree of downregulation. D) PicoGreen® proliferation assay of MM cells treated with IL-6, IL-
10, neutralizing antibodies or a combination of them. (N ¼ 3 independent experiments, *p < 0.05, * *p < 0.01, * * *p < 0.001).
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Consistent with these results, upstream regulator analysis indicates
that many cytokines are involved in the “inﬂammatory response” as
potential upstream regulators. The “upstream analysis” tool enables a
causal interpretation of the data [38] and conﬁrmed that IL-6, previously
reported to play an essential role in MM progression [52], and IL-10, an
anti-inﬂammatory cytokine with important immunoregulatory functions
[53–55], can be integrated within a mechanistic network that may ac-
count for the previously discussed gene up-regulation.
Furthermore, we have identiﬁed a synergistic mechanism between IL-
6 and IL-10 that sustains the crosstalk-dependent proliferation of MM
cells. Clinical studies conﬁrm that both IL-6 and IL-10 are present at high
concentrations in the serum of MM patients, and such serum concen-
trations strongly correlate with the disease stage [56,57]. The underlying
mechanisms that account for these observations can be, at least in part,
explained by our results.
Moreover, in accordance with the importance of Stat3 activation in
IL-6 and IL-10 signaling [43–45], the array studies revealed higher levels
of phospho-Stat3 in co-cultured cells. Stat3 is a multi-functional factor
that is known to be important for regulating cell proliferation, differen-
tiation, survival, and inﬂammatory response. Numerous studies suggest
that aberrant activation of Stat3 promotes survival and proliferation of
MM cells, and our results support these ﬁndings [58–60].
According to the literature, Multiple Myeloma (MM) patient-derived
MSC differ in the production of cytokines compared to their normal
counterparts [10,11]. It is unclear whether these abnormalities are ac-
quired byMSC after exposure to MM cells or if they are primary. Previous
results suggest that MM-MSC are intrinsically abnormal and remain as
such despite being removed from the myeloma cell inﬂuence. However,
an alternative explanation is that MM-MSC are only temporarily modi-
ﬁed in response to MM cells [13,61,62]. Our results indicate that, after
co-culture with MM cells, normal MSC can become in vitro MM-MSC,
displaying some of the essential characteristics of patient-derived
MM-MSC [63].
Although 3D models can mimic in vivo conditions better than 2D
systems and provide valuable insights into the MM microenvironment,
they do not fully resemble the physiological environment. For this
reason, additional investigations testing the relevance of our ﬁndings on
primary tumors are necessary, and should be the focus of future studies.
5. Conclusions
The present study offers signiﬁcant new insights into the paracrine
crosstalk between MSC and MM cells. Our ﬁndings suggest that IL-6/IL-
10 signaling pathways may be crucial for the progression of MM, and
therefore they may represent attractive therapeutic targets. We have
shown that the inhibition of the synergistic IL-6/10 signaling pathway
reduces the proliferation of MM cells.
Overall, our new 3D in vitro model based on a wholly synthetic,
thermoresponsive hydrogel conﬁrms that adjacent MSC and MM cells
profoundly affect each other. This causes transcriptional activation and
modiﬁes the expression of speciﬁc signals, leading to greater prolifera-
tion of MM cells. Thus, we hypothesize that normal MSC revert to a
“transformed” state in vivo which should be able to stimulate the disease
progression. Further research is required to test this hypothesis and
validate the efﬁcacy of agents targeting MSC. This study has highlighted
the potential scientiﬁc value in evaluating MM in the context of its BM
microenvironment. In this perspective, future therapies that target not
only tumor cells but also “accessory” cells could be very promising.
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